MedTrace Logo

Study of the PI3K Inhibitor SL-901 in Patients With Advanced Solid Tumors

NCT05382936 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2025-01-09

Study results available
· View outcomes & findings →

Summary

Study STML-901-0119 was a dose-escalation study evaluating multiple doses and schedules of orally administered SL-901 in patients with advanced solid tumors.

Conditions

  • Advanced Solid Tumor

Interventions

DRUG

SL-901

Patients took study medication daily, with dosage based on their assigned cohort and regimen.

Sponsors & Collaborators

  • Stemline Therapeutics, Inc.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-19
Primary Completion
2023-05-05
Completion
2023-05-05

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05382936 on ClinicalTrials.gov